Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.81 |
| ▸ | TACR2 | P21452 | 6/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TACR1 | P25103 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447403 | 0.89 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6447410 | 0.89 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6452173 | 0.89 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4603548 | 0.84 | TACR3 (0.88) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4602442 | 0.82 | TACR3 (0.85) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14094503 | 0.81 | TACR3 (0.83) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4667841 | 0.80 | TACR3 (0.78) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4601554 | 0.79 | TACR3 (0.79) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3963611 | 0.79 | TACR3 (1.00) | TACR3TACR2CYP3A4 | |
| SCHEMBL4878498 | 0.79 | TACR3 (0.76) | TACR3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482457-B2 | Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands | MERCK SHARP & DOHME | 2009-01-27 | — | — | US | claimed |
| US-20060089348-A1 | Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2006-04-27 | — | — | US | claimed |
| EP-1594844-A1 | SUBSTITUTED QUINOLINE-4-CARBOXYLIC HYDRAZIDES AS NK-2/NK-3 RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2005-11-16 | — | — | EP | claimed |
| WO-2004072045-A1 | SUBSTITUTED QUINOLINE-4-CARBOXYLIC HYDRAZIDES AS NK-2/NK-3 RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2004-08-26 | — | — | WO | claimed |
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-10-29 | — | — | US | disclosed |
| US-7560570-B2 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-14 | — | — | US | disclosed |
| US-7482457-B2 | Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands | MERCK SHARP & DOHME | 2009-01-27 | — | — | US | disclosed |
| US-20070203119-A1 | Combination Therapy For The Treatment Of Schizophrenia | MERCK SHARPE & DOHME LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20060089348-A1 | Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2006-04-27 | — | — | US | disclosed |
| EP-1594844-A1 | SUBSTITUTED QUINOLINE-4-CARBOXYLIC HYDRAZIDES AS NK-2/NK-3 RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-20050239785-A1 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-10-27 | — | — | US | disclosed |
| US-6891043-B2 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2004072045-A1 | SUBSTITUTED QUINOLINE-4-CARBOXYLIC HYDRAZIDES AS NK-2/NK-3 RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| US-6462054-B1 | ALPHA KETO HETEROCYCLIC PHARMACOPHORE; COMPLEMENTARY BINDING BY ELECTROPHILIC CARBONYL AND WEAKLY BASIC NITROGEN OF SUCH AS OXAZOLOPYRIDINE GROUP; SLEEP AIDS OR ANALGESICS; PRESERVING ENDOGENOUS LEVELS OF OLEAMIDE AND ANANDAMIDE | THE SCRIPPS RESEARCH INSTITUTE | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089348-A1 | Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands | HRH4, HRH3, HRH2 | TACR3 8/4885TACR2 6/4885CYP1A2 821/4885 |
| US-20070203119-A1 | Combination Therapy For The Treatment Of Schizophrenia | HTR3B, HTR3A, TACR2 | TACR3 15/4885TACR2 3/4885CYP1A2 780/4885 |
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, CNR2 | TACR3 1012/4885TACR2 321/4885CYP1A2 120/4885 |
| US-20050239785-A1 | Inhibitors of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | TACR3 1012/4885TACR2 321/4885CYP1A2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.